Literature DB >> 8093278

Zalcitabine and didanosine.

J J Lipsky1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8093278     DOI： 10.1016/0140-6736(93)92496-g

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

Review 1.  Tolerabilities of antiretrovirals in paediatric HIV infection.

Authors:  Daniel Avi Lemberg; Pamela Palasanthiran; Michele Goode; John B Ziegler
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 2.  Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection.

Authors:  J C Adkins; D H Peters; D Faulds
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

Review 3.  Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations.

Authors:  M Barry; S Gibbons; D Back; F Mulcahy
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

4.  Proficiency of internal medicine residents in outpatient care of patients with HIV infection.

Authors:  P Schultz; A B Bindman; M Cooke
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

Review 5.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.